Company / Net Income
Cytokinetics Net Income History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Net Income
-$785.0M
FY2025
5-year range
-$785.0M / -$215.3M
FY2021-FY2025
Trend
-33.2%
vs FY2024
Sector context
#207 of 216
Health Care
What the data says
Among 216 Health Care companies, Cytokinetics is in the bottom 4% for net income. Net Income has declined for 7 consecutive years, from -$106M in FY2018 to -$785M in FY2025.
Based on SEC 10-K filings.
-$785M in FY2025.
Declined from -$526M to -$785M over the past 2 years.
Health Care sector context is included.
Net Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 4% in Health CareTop 96% of 216This company -$785.0M Sector average $454.3M
▼
-272.8% below sector average
Key checks
Key Insights
- Cytokinetics's net income has declined for 7 consecutive years.
- In FY2025, net income decreased 33.2% year-over-year.
- Ranks #207 out of 216 companies in the Health Care sector.
- Peak net income was recorded in FY2016.
Company context
Key Data Points
- Altman Z-Score -3.12 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Net IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$785.0M | -33.2% |
| FY2024 | -$589.5M | -12.0% |
| FY2023 | -$526.2M | -35.3% |
| FY2022 | -$389.0M | -80.6% |
| FY2021 | -$215.3M | -69.2% |
| FY2020 | -$127.3M | -4.6% |
| FY2019 | -$121.7M | -14.5% |
| FY2018 | -$106.3M | +16.8% |
| FY2017 | -$127.8M | -876.7% |
| FY2016 | $16.5M | +143.9% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026